GeneDx Holdings Corp. operates as a genomic diagnostics and health intelligence company that translates complex genomic data into clinical answers. The company's business model is centered on providing high-complexity clinical genetic testing services to hospitals, genetic specialists, pediatricians, and health systems. GeneDx generates the vast majority of its revenue—over 80%—from third-party insurance reimbursements for patient testing, with the remainder coming from institutional customers, self-pay patients, and biopharma partnerships. The company's core products are its whole exome sequencing (WES) and whole genome sequencing (WGS) tests, which account for the bulk of its test volume and revenue. Key offerings include XomeDx, GenomeSeqDx, and rapid turnaround tests designed for neonatal intensive care units (NICUs). GeneDx also provides targeted variant testing and prenatal genetic testing. Its competitive position is supported by its proprietary "GeneDx Infinity" database, which contains over one million clinically sequenced exomes and genomes alongside millions of phenotypic data points. This extensive dataset enhances the company's ability to interpret variants of unknown significance in the rare disease diagnostics market. Additionally, GeneDx partners with biopharmaceutical companies to support drug discovery and clinical trial enrollment for rare diseases. The company operates primarily in the United States, with its headquarters in Connecticut and its main clinical laboratory in Maryland.
